The global antihyperlipidemic drugs market size reached USD 13.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.6 Billion by 2033, exhibiting a growth rate (CAGR) of 3.9% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 13.1 Billion |
Market Forecast in 2033
|
USD 18.6 Billion |
Market Growth Rate 2025-2033 | 3.9% |
Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient’s cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.
The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on drug class, route of administration and distribution channel.
Breakup by Drug Class:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Class, Route of Administration, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global antihyperlipidemic drugs market was valued at USD 13.1 Billion in 2024.
We expect the global antihyperlipidemic drugs market to exhibit a CAGR of 3.9% during 2025-2033.
The growing usage of antihyperlipidemic drugs to aid in lowering the serum levels of cholesterol and various lipids in the blood is primarily driving the global antihyperlipidemic drugs market.
The sudden outbreak of the COVID-19 pandemic has led to the rising demand for antihyperlipidemic drugs to treat the onset of coronary artery disease among the patients, which is an adverse side-effect of the coronavirus disease.
Based on the drug class, the global antihyperlipidemic drugs market has been segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and others. Currently, statins hold the majority of the total market share.
Based on the distribution channel, the global antihyperlipidemic drugs market can be divided into hospital pharmacies, retail stores, and online retailers. Among these, hospital pharmacies exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global antihyperlipidemic drugs market include Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi S.A.